首页> 外文会议>American Peptide Symposium >Proteinous Microspheres Containing KLVFF Peptides Sequester Amyloid-Beta Protein and Inhibit its Aggregation
【24h】

Proteinous Microspheres Containing KLVFF Peptides Sequester Amyloid-Beta Protein and Inhibit its Aggregation

机译:含有Klvff肽螯合淀粉样蛋白β蛋白的蛋白质微球,并抑制其聚集

获取原文

摘要

Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized clinically by progressive impairment in memory and cognition. The neuropathology of AD is characterized by extraneuronal deposition of amyloid-β (AP) and neurofibrillary tangles. Aβ is a short polypeptide (40 to 43 amino acids) that at sufficiently high concentration tend to selfassemble into soluble aggregates, which in turn accumulate as amyloids [1]. The aggregates are associated with pathological changes in the surrounding brain neurons that lead to neuronal death and synaptic loss. Therefore, interfering with Aβ formation and aggregation or sequestering its accumulation in the brain are promising strategies for AD therapy. Lowe et al. have showed that compounds containing a recognition element KLVFF (residues 16-20 in A P) can bind to the homologous sequence in Aβ through hydrophobic and n-n interactions and disrupt its aggregation, thus protecting neurons from Aβ-associated toxicity. Therefore, this fragment was served as a lead compound for the development of inhibitory agents that are aimed at preventing Aβ aggregation in vivo [2]. Moreover, it was shown that dendrimeric analog of KLVFF display superior activity compared to the monomeric KLVFF [3]. The concept of multivalency to enhance the affinity and specificity of a ligand to its receptor is an important feature in biology. Here, we describe the design, preparation and characterization of novel proteinous microspheres (PM) decorated with KLVFF peptides at their surface, and demonstrate their efficacy to inhibit Aβ aggregation by sequestering it from the solution. The preparation of these microspheres is based on sonochemical approach that uses high-intensity ultrasound to make aqueous suspensions filled with water-insoluble liquids [4]. The microspheres are spherical microcapsules that are generated from intermolecular disulfide bonds between protein's cysteines. We snowed that the surface of such microspheres can be readily modified with different thiol containing substances through the exchange reaction with the disulphide groups of bovine serum albumin; and they can effectively encapsulate different substances such as drugs or contrasting agents.
机译:阿尔茨海默氏病(AD)是一种进行性神经变性疾病由在记忆和认知损害渐进临床特征。 AD的神经病理学的特征在于淀粉样蛋白β(AP)和神经纤维缠结的沉积元外。 Aβ是一个短的多肽(40至43个氨基酸),在足够高的浓度往往会自组装成可溶性聚集体,这又累加作为淀粉样蛋白[1]。这些聚集体与周围脑神经元,导致神经元死亡和突触损失病理变化有关。因此,与Aβ的形成和聚集干扰或隔绝其在大脑中的积累是有希望的AD治疗策略。 Lowe等人。已经表明,含有识别元件KLVFF(残基16-20中所述的P)的化合物可通过疏水和N-N相互作用结合在Aβ的同源序列和破坏其聚集,从而保护神经元免于Aβ相关毒性。因此,此片段充当了抑制剂的开发先导化合物的是旨在防止在体内[2]Aβ聚集。此外,已显示,相对于单体KLVFF [3] KLVFF的树枝状模拟显示出优越的活性。多价的概念,以提高配体的亲和力和特异性受体是生物学的一个重要特征。这里,我们描述饰以在它们的表面KLVFF肽新颖蛋白质性微球(PM)的设计,制备和表征,并证明其功效通过从溶液螯合它以抑制Aβ聚集。这些微球的制备是基于使用高强度超声以使填充有不溶于水的液体[4]水性混悬剂声化学方法。该微球是被来自蛋白质的半胱氨酸之间的分子间二硫键产生的球面微胶囊。我们下雪,这种微球的表面可以通过用牛血清白蛋白的二硫化物基团的交换反应不同含硫醇的物质容易地修改;他们可以有效地封装不同的物质,如药物或造影剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号